Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma
1 clinical trials · Condition
◉ Watch Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma
| Record | Firm | Date |
|---|---|---|
| Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma (NCT04984434) | Shandong New Time Pharmaceutical Co., LTD | 2021-07-30 |
Track Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma automatically
Every clearance here is in the API, with alerts when new ones post.